![](https://sourceonhealth.wpenginepowered.com/wp-content/uploads/2019/04/SLIHCQ-title-1.png)
HB 1794 – Texas
Status: Inactive / DeadYear Introduced: 2019
Link: https://capitol.texas.gov/tlodocs/86R/billtext/html/HB01794I.htm
Relating to price transparency for certain prescription drugs; authorizing civil penalties. Requires a drug manufacturer of an expensive drug sold or offered for sale to submit a report to the department for each expensive drug the total research and development costs for the drug and other related costs. Not later than the 60th day before the date a price increase takes effect, a manufacturer shall submit written notice to the department before the manufacturer increases the average wholesale price or wholesale acquisition cost of an expensive drug by more than: (1) the lesser of 10 percent or $2,500 during a 12-month period; or (2) 15 percent cumulatively during any 24-month period, and provide justification for the increase.
Return to Database Search
© 2018- The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.
Associated Litigation:
No items found